Adicet Bio Inc. (ACET)
NASDAQ: ACET
· Real-Time Price · USD
0.65
-0.02 (-2.69%)
At close: May 14, 2025, 3:59 PM
0.64
-1.85%
After-hours: May 14, 2025, 06:31 PM EDT
-2.69% (1D)
| Bid | 0.63 |
| Market Cap | 53.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -117.12M |
| EPS (ttm) | -1.29 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | -0.54 |
| Analyst | Buy |
| Ask | 0.7 |
| Volume | 486,911 |
| Avg. Volume (20D) | 512,520 |
| Open | 0.66 |
| Previous Close | 0.67 |
| Day's Range | 0.64 - 0.67 |
| 52-Week Range | 0.45 - 1.71 |
| Beta | 1.77 |
About ACET
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACET
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACET stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-18.65%
Adicet Bio shares are tracing lower. The company r...
Unlock content with
Pro Subscription
3 months ago
+9.79%
Adicet Bio shares are trading higher after the company was granted FDA Fast Track designation to ADI-001 for treating refractory systemic lupus erythematosus with extrarenal involvement.
2 weeks ago · businesswire.com
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
1 month ago · businesswire.com
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
